Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update - Wikidata - wikimedia - TriplyDB

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

http://www.wikidata.org/entity/Q30356434

about

Non-small cell lung cancer: current treatment and future advances Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date Clinical potential of necitumumab in non-small cell lung carcinoma China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)A critical review of recent developments in radiotherapy for non-small cell lung cancer Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence.First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study.Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy.Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients.Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.Targeting BET bromodomain proteins in solid tumors Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists.Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC.Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.

P2860

Q26740333-83ED337F-C381-4DAC-9758-9006D75FC537 Q26745422-DB3C1CDA-9970-4F31-A99C-4F7FC8496306 Q26745427-26AAF715-BAD3-435E-A18F-9F1A7A49C050 Q28067610-68437D6F-E26B-4157-81E1-63CC6759540D Q28072850-870B4F17-E6D9-479B-B7A4-BF7AD43B35AE Q28073920-50FB4001-323C-4E79-B69F-ECA3F03AE661 Q28079625-E9EE8838-5264-44B3-BD8B-D3E6A4B4DF0A Q28597805-2A555F74-0385-471E-8814-A521FAD15702 Q31125762-2EC80B35-F16B-421B-8E63-F503C50FF2F6 Q31133861-CF022B6D-49F6-4544-84ED-D4C334636FAE Q33435610-5578D16F-5589-41D8-8DF1-17E54FF7315C Q33439970-57E8B050-05C2-4FC6-BB28-F81E8477A3FD Q33439985-720E2878-CD6D-4605-A2E3-792C6B4E37A0 Q33735646-A5B963C2-F5A3-45BD-B022-F1A69F67BF05 Q33760613-0FBFF258-0226-4DD6-B274-29C839C2C971 Q33873095-2CA27C5C-F0F8-4B15-9A4D-3C11560306B9 Q33875284-C1F90540-6AF7-46DA-B54F-41FF4C1C08E8 Q34550460-689FE8CA-AC8D-4733-ADA1-02A01FB70D88 Q36103228-D5667025-A62D-470D-B688-1BA5C22BE8D7 Q36148697-D15470E1-BF29-4B99-8CED-CDB78C34EABD Q36202696-D8DA46AF-B155-44E1-9D30-90F16E6F0D7C Q36264911-FDB66315-D8D0-47CE-9E4F-FBB85811B114 Q36356699-50434FD2-AA12-49E7-8B0A-EEC3F0B572C2 Q36363579-5A810152-60A3-4B17-A083-61634A633855 Q36490370-8EAF8D01-7995-49D4-A8F2-DB79FBCD3D23 Q36854048-DD5138F0-F6A9-4D3C-AFCC-A20BAC0645D9 Q37041209-EF5A0E41-3B63-4C52-891D-11B4C0DC866C Q37051546-89989B0C-FCC3-4C5A-866A-ADB2B2EA9B46 Q37264931-361A95FA-8B2B-4E51-B1A9-E67242582160 Q37534932-2BB66CD8-17F5-4D1B-9F05-1EFFCE872948 Q37539775-7BB9CABA-0B54-4CC3-9D7A-DA95B76654D3 Q37569995-97E37D73-682B-4543-ACA2-944DB4DDB80D Q37619860-4D81F7D1-78FE-469D-84C3-CA9AF4C9CB90 Q37672002-05B0E9FB-71AE-4116-8B8E-2F5B3B94E8A2 Q37708814-1E002483-C396-4984-A812-B7BC5B537FA0 Q37721218-99F208D8-EEA7-4A29-9D37-7694C5F254AC Q37725971-83F32FE9-95AB-437D-B4A8-CB107D2AB620 Q37731321-038E6C81-3FC0-4969-9958-28D46FEE06F7 Q38372645-9737BC4C-799F-41CD-806D-D6AB528EBBFA Q38598931-DCEF07FF-0C7D-45B1-BCF5-B2E1A676E30E

P2860

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

http://www.wikidata.org/entity/Q30356434

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Systemic Therapy for Stage IV ...... ical Practice Guideline Update

@ast

Systemic Therapy for Stage IV ...... ical Practice Guideline Update

@en

type

label

Systemic Therapy for Stage IV ...... ical Practice Guideline Update

@ast

Systemic Therapy for Stage IV ...... ical Practice Guideline Update

@en

prefLabel

Systemic Therapy for Stage IV ...... ical Practice Guideline Update

@ast

Systemic Therapy for Stage IV ...... ical Practice Guideline Update

@en

P1433

Q30356434-F97E7C8E-59A0-468B-9822-BEAB5F3E6CD0

P1476

Q30356434-96597D13-7941-498B-99AB-F90829912607

P2093

Q30356434-01F08FC7-96D1-490A-B65A-87AB7E8FE8C2

Q30356434-094322F0-A49A-4B7C-8369-0E3697D2D5C9

Q30356434-0B330106-C5ED-4BC4-BA11-04138F393F0D

Q30356434-391C27C7-48DD-4BCA-B3AE-ED8EF3E95CFE

Q30356434-40515B4F-8A8D-413A-B28A-088F039DFE7A

Q30356434-5D2E6921-9350-40E2-AAAD-25978AAC60DC

Q30356434-69034F10-B921-4602-B1E2-ECB6BCF874EC

Q30356434-6E031A42-5410-4229-A1E5-95252AD105D1

Q30356434-6F15A1E7-7C2F-463F-9041-BBD8579C6D21

Q30356434-95D57AEC-42A7-4688-A77D-10588585B9A1

P2860

Q30356434-01F1EA91-642C-4B2A-A1DB-6CBAAF2CCAB9

Q30356434-04A38643-2652-488A-9069-00DF89DAC8B4

Q30356434-05D898F5-3100-4D35-AF61-C841058129AD

Q30356434-07160DA3-E791-4079-818D-25BF1F481C97

Q30356434-08DA7C5C-EA3D-4FB3-9957-65FA565B15CE

Q30356434-09400F81-A8B1-47D8-8C14-436514BFBC43

Q30356434-0BD242F9-A4DF-4300-A1E8-87A4CD1E97AE

Q30356434-0C50953A-8B97-4068-B12D-950FC8154CF6

Q30356434-0EB7800A-EEC1-4E80-8A0A-455C9251181E

Q30356434-12524927-05D0-4993-9D64-5070067AFB5C

P304

Q30356434-67102692-77C6-413D-B5E3-B4DFA5A5663D

P31

Q30356434-72004BA1-BE52-4BE9-A566-1C0A8A6A6820

P356

Q30356434-FD993252-14FC-4683-8249-22B3C55B8D64

P407

Q30356434-58D5B598-EF70-4ECE-81C9-EC23B09D6BC1

P433

Q30356434-F0B4909A-FE67-443B-B6D4-095941B50A12

P478

Q30356434-F89D065B-9845-4184-AA08-7981B5B96DC5

P50

Q30356434-16DE4465-AB9F-426E-8685-91CCAA3154F3

Q30356434-2FE59124-9C3B-486E-ACC8-14EAF3F74E41

P577

Q30356434-CD46C947-0776-4B6F-8B73-9A786DD1ECF4

P698

Q30356434-4521F68A-8AA8-446B-AF64-446B5D77D341

P932

Q30356434-11E2AF61-822C-4717-ADF0-DC5A1FF68063

P356

JCO.2015.62.1342

P1433

Journal of Clinical Oncology

P1476

Systemic Therapy for Stage IV ...... ical Practice Guideline Update

@en

P2093

Ajeet Gajra

http://www.w3.org/2001/XMLSchema#string

American Society of Clinical Oncology Clinical Practice

http://www.w3.org/2001/XMLSchema#string

Christopher G Azzoli

http://www.w3.org/2001/XMLSchema#string

David H Johnson

http://www.w3.org/2001/XMLSchema#string

David Trent

http://www.w3.org/2001/XMLSchema#string

Gregory A Masters

http://www.w3.org/2001/XMLSchema#string

Joan H Schiller

http://www.w3.org/2001/XMLSchema#string

John R Strawn

http://www.w3.org/2001/XMLSchema#string

Julie R Brahmer

http://www.w3.org/2001/XMLSchema#string

Nancy Rackear

http://www.w3.org/2001/XMLSchema#string

P2860

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer

Early specialty palliative care--translating data in oncology into practice

Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

P304

3488-3515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.62.1342

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

Thomas J. Smith

P577

2015-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26324367

http://www.w3.org/2001/XMLSchema#string

P932

5019421

http://www.w3.org/2001/XMLSchema#string